|
T28036 |
MI-2-2
|
MI22,MI 2 2 |
Histone Methyltransferase
|
|
MI-2-2 is an inhibitor of bivalent protein-protein interaction between menin and MLL with an IC50 of 46 nM. MI-2-2 binds to menin with Kd of 22 nM. |
|
T2643 |
MI-3
|
Menin-MLL Inhibitor,Menin-MLL inhibitor 3,MI 3 |
Apoptosis
,
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-3 (Menin-MLL Inhibitor) (Menin-MLL Inhibitor) is an effective inhibitor of Menin-MLL interaction (IC50: 648 nM). |
|
T9399 |
Menin-MLL inhibitor 20
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
Menin-MLL inhibitor 20 is an irreversible inhibitor of menin-MLL interaction with antitumor activities. |
|
T2649 |
Menin-MLL inhibitor MI-2
|
Menin-MLL Inhibitor,MI2,MI-2,Menin-MLL inhibitor 2,MI 2 |
Apoptosis
,
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
Menin-MLL inhibitor MI-2 (MI2) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM. |
|
TQ0069 |
MI-503
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-503 is a highly effective and orally bioavailable inhibitor of the menin-mLL interaction. |
|
T11925 |
M‑89
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia... |
|
T16072 |
MI-538
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM). |
|
T13336 |
VTP50469
|
|
Apoptosis
,
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
VTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity. |
|
TQ0058 |
MI-463
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-463 is a potent and orally bioavailable inhibitor of the menin-mLL interaction (IC50: 15.3 nM). |
|
T12002 |
Menin-MLL inhibitor 4
|
|
Others
|
|
Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction . |
|
T22978 |
MI-2 (hydrochloride)
|
|
Others
|
|
MI-2 (Menin-MLL Inhibitor) is an effective menin-MLL interaction inhibitor (IC50: 446 ± 28 nM). |
|
T72135 |
(1s,4s)-Menin-MLL inhibitor-23
|
|
|
|
(1s,4s)-Menin-MLL Inhibitor-23, an enantiomer of Menin-MLL Inhibitor-23 (Example 99A), functions as an inhibitor of the menin-MLL interaction [1]. |
|
T24484 |
ML399
|
VU-0516340,VU 0516340,ML-399,VU0516340,ML 399 |
|
|
ML399 is the menin-- MLL interaction inhibitor that acts by demonstrating strong and selective effects in MLL leukemia cells and validating specific mechanism of action. |
|
T39585 |
Ziftomenib
|
KO-539 |
|
|
Ziftomenib is a menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151). |
|
T13336L |
VTP50469 fumarate
|
|
Others
|
|
VTP50469 fumarate is a highly selective and orally active inhibitor of Menin-MLL interaction (Ki: 104 pM), and has potently anti-leukemia activity. |
|
T61735 |
MI-1
|
|
|
|
MI-1 inhibits Menin-MLL interaction with an IC 50 of 1.9 μM [1]. |
|
T24472 |
MIV-6R
|
MIV6R,VU05163101,VU0516310-1,VU0516310 1,MIV 6R |
|
|
MIV-6R is an inhibitor of the menin- MLL interaction that acts by demonstrating strong and selective effects in MLL leukemia cells and validating specific mechanisms of action. |
|
T15831 |
M-525
|
|
Others
|
|
M-525 binds to menin (IC50: 3 nM) and achieves low nanomolar potencies in cell growth inhibition and in the suppression of MLL regulated gene expression in MLL leukemia cells. M-525 is a first-in-class, highly potent, ir... |
|
T27134 |
DCYM21
|
DC YM 21,DC-YM21,DCYM-21,DC_YM21,DC YM21 |
|
|
DCYM21 is an inhibitor of menin-MLL interaction. DCYM21 demonstrates potent and selective blockage of proliferation and induces both cell cycle arrest and differentiation of leukemia cells harboring MLL translocations. |
|
T79117 |
Menin-MLL inhibitor 27
|
|
Epigenetic Reader Domain
|
|
Menin-MLL inhibitor 27 effectively inhibits the interaction between Menin and MLL, serving as a potential tool in cancer research, particularly for acute myeloid leukemia (AML) [1]. |
|
T39938 |
M-1211
|
|
|
|
M 1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression. |
|
T24463 |
MI-1481
|
MI 1481 |
|
|
MI-1481 is an effective MML1 inhibitor (IC50: 3.6 nM). MI-1481 showed very potent inhibition of the menin-MLL1 interaction (IC50: 3.6 nM). MI-1481 also demonstrates pronounced activity in MLL leukemia cells and in vivo i... |
|
T39937 |
M-808
|
|
|
|
M-808 is a potent and efficacious covalent inhibitor, targeting the interaction between Menin and MLL. It demonstrates a high binding affinity with an IC50 value of 2.6 nM. |
|
T69629 |
M‑89 MLL inhibitor
|
|
|
|
M‑89 is a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein−Protein Interaction (Kd = 1.4 nM; IC50 = 25nM). M-89 binds to menin with a Kd value of 1.4 nM and effectively engages cellular men... |
|
T79737 |
Menin-MLL inhibitor 29
|
|
Epigenetic Reader Domain
|
|
Menin-MLL Inhibitor 29 (Compound C1) is a Menin-MLL protein-protein interaction (PPI) inhibitor that demonstrates high affinity to Menin with a dissociation constant (K D) of 138 nM and impedes Menin's interaction with M... |
